Stay updated on DARIA Trial: Daratumumab + Ixazomib in Multiple Myeloma
Sign up to get notified when there's something new on the DARIA Trial: Daratumumab + Ixazomib in Multiple Myeloma page.

Latest updates to the DARIA Trial: Daratumumab + Ixazomib in Multiple Myeloma page
- CheckyesterdayChange DetectedThe page’s disease label and a related topics section linking to MedlinePlus Genetics were removed, reducing visibility of the condition being studied and access to related resources.SummaryDifference0.2%

- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedA new revision label v3.5.4 was added and the previous label v3.5.3 was removed. This update reflects an adjustment to the page's version information.SummaryDifference0.1%

- Check22 days agoNo Change Detected
- Check37 days agoChange DetectedThe ClinicalTrials.gov page’s displayed revision/version tag has been incremented from v3.5.2 to v3.5.3, indicating a site update rather than a change to the underlying study information.SummaryDifference0.1%

- Check44 days agoChange DetectedAdded Revision: v3.5.2; removed entries for Multiple myeloma, related topics, MedlinePlus Genetics, and Revision: v3.5.0.SummaryDifference0.2%

- Check58 days agoChange DetectedUI/layout adjustments are visible, with some sections duplicated likely due to rendering. No new or removed critical trial details (eligibility criteria, outcomes, or study purpose) are evident in the changes.SummaryDifference0.1%

- Check66 days agoChange DetectedRemoved references to 'Multiple Myeloma' and to 'MedlinePlus Genetics' from the page's related topics. This reduces explicit disease context and cross-links that help users discover and understand the study.SummaryDifference0.2%

Stay in the know with updates to DARIA Trial: Daratumumab + Ixazomib in Multiple Myeloma
Enter your email address, and we'll notify you when there's something new on the DARIA Trial: Daratumumab + Ixazomib in Multiple Myeloma page.